What is Annoroad?
Founded in 2012 and headquartered in Beijing, Annoroad Gene Technology is a leading enterprise in China's genomics industry. It stands out as a premier NIPT service provider and a best-in-class medical genomics center in Asia. The company specializes in applying next-generation genomics to human health and life science research. Annoroad has garnered numerous accolades, including designations as a national high-tech enterprise and approval for high-throughput sequencing clinical applications. Its advanced capabilities are supported by proprietary genome sequencing and bioinformatics technologies, alongside high-throughput sequencing and high-performance computing platforms. Annoroad has also developed its own high-throughput sequencer, NextSeq 550AR, and a cloud-based genomic big data platform, SolarGenomics, establishing a comprehensive product system across the industry chain.
How much funding has Annoroad raised?
Annoroad has raised a total of $100M across 1 funding round:
Series C
$100M
Series C (2017): $100M with participation from SBCVC, SAIF Partners, ShenZhen GTJA Investment Group, and Ping An Ventures
Key Investors in Annoroad
SBCVC
SBCVC is a venture capital and private equity firm established in China, focusing on high-growth companies in sectors including TMT, clean technology, and healthcare. They provide capital and strategic support across all company stages.
SAIF Partners
SAIF Partners is a private equity firm specializing in growth capital for companies in China and the broader Asian region, with interests in TMT, healthcare, and new materials.
Ping An Ventures
Ping An Ventures, part of Ping An Insurance Group, focuses on investments within the financial services and technology sectors, leveraging the group's extensive network in insurance, banking, and investment banking.
What's next for Annoroad?
With its substantial enterprise-level investment, Annoroad is strategically positioned for accelerated growth and further innovation in the rapidly evolving genomics landscape. The company's focus on precision medicine, genetic engineering, and genomic big data services, coupled with its strong industry presence, suggests a future emphasis on expanding its research and development initiatives, enhancing its medical testing and research services, and potentially exploring new market opportunities. This significant capital infusion will likely fuel advancements in its proprietary technologies and solidify its leadership in both domestic and international markets, particularly within Asia.
See full Annoroad company page
